258 related articles for article (PubMed ID: 30257357)
1. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
Xu ZH; Yao TZ; Liu W
Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
Li H; Dai S; Zhen T; Shi H; Zhang F; Yang Y; Kang L; Liang Y; Han A
Eur J Cancer; 2014 Apr; 50(6):1207-21. PubMed ID: 24412052
[TBL] [Abstract][Full Text] [Related]
4. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
5. MiR-378a-3p enhances adipogenesis by targeting mitogen-activated protein kinase 1.
Huang N; Wang J; Xie W; Lyu Q; Wu J; He J; Qiu W; Xu N; Zhang Y
Biochem Biophys Res Commun; 2015 Jan; 457(1):37-42. PubMed ID: 25529446
[TBL] [Abstract][Full Text] [Related]
6. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1.
Chen J; Li G
Biomed Pharmacother; 2018 Nov; 107():997-1003. PubMed ID: 30257412
[TBL] [Abstract][Full Text] [Related]
7. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
9. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of miR-378a-3p induces decidual cell apoptosis: a possible mechanism for early pregnancy loss.
Hong L; Yu T; Xu H; Hou N; Cheng Q; Lai L; Wang Q; Sheng J; Huang H
Hum Reprod; 2018 Jan; 33(1):11-22. PubMed ID: 29165645
[TBL] [Abstract][Full Text] [Related]
11. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes.
Chen W; Du J; Li X; Su J; Huang Y; Ding N; Zhang M; Jiang S
Pharmacogenomics; 2017 Dec; 18(18):1671-1682. PubMed ID: 29173002
[TBL] [Abstract][Full Text] [Related]
12. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
13. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
14. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
16. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling.
Yang Q; Zhao S; Shi Z; Cao L; Liu J; Pan T; Zhou D; Zhang J
J Exp Clin Cancer Res; 2021 Apr; 40(1):120. PubMed ID: 33823894
[TBL] [Abstract][Full Text] [Related]
18. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4.
Chanjiao Y; Chunyan C; Xiaoxin Q; Youjian H
Immun Inflamm Dis; 2021 Mar; 9(1):108-119. PubMed ID: 33159506
[TBL] [Abstract][Full Text] [Related]
20. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
